Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| BetahistineNCT00466869 | OBEcure Ltd.PHASE2 | TERMINATED Sponsor decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-09-26 |
| GabapentinNCT00533455 | Minneapolis Veterans Affairs Medical CenterPHASE3 | TERMINATED Failure to recruit due to polypharmacy | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-09-24 |
| AlfuzosinNCT00454402 | SanofiPHASE3 | TERMINATED Discontinued due to incomplete recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-09-24 |
| topiramate (drug)NCT00296959 | University Health Network, TorontoPHASE2 | TERMINATED early termination due to slow recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-09-20 |
| tetrahydrobiopterin (BH4)NCT00432822 | Orphanetics Pharma Entwicklungs GmbHPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-09-20 |
| ICA-17043NCT00294541 | IcagenPHASE3 | TERMINATED Lack of efficacy demonstrated in study ICA-17043-10 | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-09-11 |
| letrozoleNCT00267553 | Intarcia TherapeuticsPHASE3 | TERMINATED This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-09-10 |
| toremifeneNCT00267553 | Intarcia TherapeuticsPHASE3 | TERMINATED This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-09-10 |
| AtamestaneNCT00267553 | Intarcia TherapeuticsPHASE3 | TERMINATED This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-09-10 |
| NX1011NCT00323024 | NITROX, LLCPHASE2 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-30 |
| BicalutamideNCT00255268 | AstraZenecaPHASE4 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-28 |
| GoserelinNCT00255268 | AstraZenecaPHASE4 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-28 |
| Estrogen receptor blockerNCT00097344 | Intarcia TherapeuticsPHASE3 | TERMINATED Identical study Biomed 777-CLP-029 did not meet superiority endpoint | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-08-23 |
| Aromatase inhibitionNCT00097344 | Intarcia TherapeuticsPHASE3 | TERMINATED Identical study Biomed 777-CLP-029 did not meet superiority endpoint | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-08-23 |
| LetrozoleNCT00097344 | Intarcia TherapeuticsPHASE3 | TERMINATED Identical study Biomed 777-CLP-029 did not meet superiority endpoint | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-08-23 |
| ToremifeneNCT00097344 | Intarcia TherapeuticsPHASE3 | TERMINATED Identical study Biomed 777-CLP-029 did not meet superiority endpoint | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-08-23 |
| AtamestaneNCT00097344 | Intarcia TherapeuticsPHASE3 | TERMINATED Identical study Biomed 777-CLP-029 did not meet superiority endpoint | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-08-23 |
| lithiumNCT00520026 | University Hospital Schleswig-HolsteinNA | TERMINATED number of enrolled individuals after 5 years still off the estimated sample size | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-08-23 |
| Valproic AcidNCT00519181 | University Hospital Pierre Zobda-QuitmanNA | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-22 |
| liposomal amphotericin B (AmBisome®)NCT00386997 | Gilead SciencesPHASE4 | TERMINATED Study closed due to recruitment challenges. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-21 |
| AlfuzosinNCT00453908 | SanofiPHASE3 | TERMINATED The study was early terminated due to slow and difficult recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-08-20 |
| HerceptinNCT00189579 | ARCAGY/ GINECO GROUPPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-17 |
| Carboplatin/TaxolNCT00061646 | AbbottPHASE2 | TERMINATED Enrollment suspended based upon interim analysis; subjects allowed to stay on study until disease progression. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-14 |
| ABT-510/Thrombospondin-1 mimeticNCT00061646 | AbbottPHASE2 | TERMINATED Enrollment suspended based upon interim analysis; subjects allowed to stay on study until disease progression. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-14 |
| Sulfadoxine PyrimethamineNCT00453856 | Albert Schweitzer Hospital, NetherlandsPHASE4 | TERMINATED The study was terminated because of Early Treatment Failure in child.The justification for this decision are concerns about safety of children. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-10 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |